Skip to main content
SpringerLink
Log in

RAASi-associated hyperkalaemia: increased risk of adverse outcomes

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. The study was funded in part by Astra-Zeneca.

Reference

  • Johnson M, et al. Outcomes in Patients with Cardiometabolic Disease Who Develop Hyperkalemia While Treated with a RAAS Inhibitor. American Heart Journal : 12 Jan 2023. Available from: URL: http://doi.org/10.1016/j.ahj.2023.01.002

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

RAASi-associated hyperkalaemia: increased risk of adverse outcomes. Reactions Weekly 1941, 11 (2023). https://doi.org/10.1007/s40278-023-32274-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-023-32274-9

Search

Navigation